Kymera Therapeutics (KYMR) Leases (2019 - 2025)
Kymera Therapeutics (KYMR) has disclosed Leases for 7 consecutive years, with $42.4 million as the latest value for Q4 2025.
- On a quarterly basis, Leases fell 10.67% to $42.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $42.4 million, a 10.67% decrease, with the full-year FY2025 number at $42.4 million, down 10.67% from a year prior.
- Leases was $42.4 million for Q4 2025 at Kymera Therapeutics, down from $42.9 million in the prior quarter.
- In the past five years, Leases ranged from a high of $56.6 million in Q1 2023 to a low of $8.9 million in Q4 2022.
- A 5-year average of $33.3 million and a median of $44.5 million in 2025 define the central range for Leases.
- Peak YoY movement for Leases: surged 508.19% in 2023, then decreased 12.85% in 2024.
- Kymera Therapeutics' Leases stood at $9.4 million in 2021, then fell by 5.48% to $8.9 million in 2022, then skyrocketed by 494.29% to $52.9 million in 2023, then fell by 10.46% to $47.4 million in 2024, then dropped by 10.67% to $42.4 million in 2025.
- Per Business Quant, the three most recent readings for KYMR's Leases are $42.4 million (Q4 2025), $42.9 million (Q3 2025), and $46.0 million (Q2 2025).